Cite
Development and Optimization of Proniosomal Formulation of Irbesartan Using a Box–Behnken Design to Enhance Oral Bioavailability: Physicochemical Characterization and In Vivo Assessment
MLA
Md. Ali Mujtaba, et al. “Development and Optimization of Proniosomal Formulation of Irbesartan Using a Box–Behnken Design to Enhance Oral Bioavailability: Physicochemical Characterization and In Vivo Assessment.” ACS Omega, vol. 9, no. 14, Mar. 2024, pp. 16346–57. EBSCOhost, https://doi.org/10.1021/acsomega.3c10506.
APA
Md. Ali Mujtaba, Mohammed Kaleem, Ragini Chaware, Ashwini Ingole, Yahya I. Asiri, Mohd. Zaheen Hassan, Vidya Sabale, Prafulla Sabale, Md. Khalid Anwer, Danish Mahmood, & Mohammed F. Aldawsari. (2024). Development and Optimization of Proniosomal Formulation of Irbesartan Using a Box–Behnken Design to Enhance Oral Bioavailability: Physicochemical Characterization and In Vivo Assessment. ACS Omega, 9(14), 16346–16357. https://doi.org/10.1021/acsomega.3c10506
Chicago
Md. Ali Mujtaba, Mohammed Kaleem, Ragini Chaware, Ashwini Ingole, Yahya I. Asiri, Mohd. Zaheen Hassan, Vidya Sabale, et al. 2024. “Development and Optimization of Proniosomal Formulation of Irbesartan Using a Box–Behnken Design to Enhance Oral Bioavailability: Physicochemical Characterization and In Vivo Assessment.” ACS Omega 9 (14): 16346–57. doi:10.1021/acsomega.3c10506.